Urine cytology and commercially available urine-based markers for monitoring of bladder urothelial carcinoma

Jose A. Karam, Yair Lotan, Shahrokh F. Shariat

Research output: Contribution to journalArticle

Abstract

Bladder cancer is currently diagnosed using cystoscopy and cytology in patients with suspicious signs and symptoms. These tests are also used to monitor patients with a history of bladder cancer. The recurrence rate for bladder cancer is high, thus necessitating long-term follow-up. Urine cytology requires an experienced cytopathologist. It has high specificity, but low sensitivity for low-grade bladder tumors. Recently, multiple non-invasive urine-based bladder cancer tests have been developed. Many markers have already been approved by the Food and Drug Administration (FDA) for bladder cancer surveillance, but only one marker is approved for detection of bladder cancer in high risk patients (NMP22 BladderChek).

Original languageEnglish (US)
Pages (from-to)48-52
Number of pages5
JournalLaboratory Medicine
Volume38
Issue number1
DOIs
StatePublished - 2007

Fingerprint

Cytology
Urinary Bladder Neoplasms
Cell Biology
Urinary Bladder
Urine
Carcinoma
Monitoring
Tumors
Cystoscopy
United States Food and Drug Administration
Signs and Symptoms
Recurrence
Sensitivity and Specificity
nuclear matrix protein 22

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Urine cytology and commercially available urine-based markers for monitoring of bladder urothelial carcinoma. / Karam, Jose A.; Lotan, Yair; Shariat, Shahrokh F.

In: Laboratory Medicine, Vol. 38, No. 1, 2007, p. 48-52.

Research output: Contribution to journalArticle

@article{8194063f668c440fab44164febcb7488,
title = "Urine cytology and commercially available urine-based markers for monitoring of bladder urothelial carcinoma",
abstract = "Bladder cancer is currently diagnosed using cystoscopy and cytology in patients with suspicious signs and symptoms. These tests are also used to monitor patients with a history of bladder cancer. The recurrence rate for bladder cancer is high, thus necessitating long-term follow-up. Urine cytology requires an experienced cytopathologist. It has high specificity, but low sensitivity for low-grade bladder tumors. Recently, multiple non-invasive urine-based bladder cancer tests have been developed. Many markers have already been approved by the Food and Drug Administration (FDA) for bladder cancer surveillance, but only one marker is approved for detection of bladder cancer in high risk patients (NMP22 BladderChek).",
author = "Karam, {Jose A.} and Yair Lotan and Shariat, {Shahrokh F.}",
year = "2007",
doi = "10.1309/DTJXKUDMQ49P80LR",
language = "English (US)",
volume = "38",
pages = "48--52",
journal = "Laboratory Medicine",
issn = "0007-5027",
publisher = "American Society of Clinical Pathologists",
number = "1",

}

TY - JOUR

T1 - Urine cytology and commercially available urine-based markers for monitoring of bladder urothelial carcinoma

AU - Karam, Jose A.

AU - Lotan, Yair

AU - Shariat, Shahrokh F.

PY - 2007

Y1 - 2007

N2 - Bladder cancer is currently diagnosed using cystoscopy and cytology in patients with suspicious signs and symptoms. These tests are also used to monitor patients with a history of bladder cancer. The recurrence rate for bladder cancer is high, thus necessitating long-term follow-up. Urine cytology requires an experienced cytopathologist. It has high specificity, but low sensitivity for low-grade bladder tumors. Recently, multiple non-invasive urine-based bladder cancer tests have been developed. Many markers have already been approved by the Food and Drug Administration (FDA) for bladder cancer surveillance, but only one marker is approved for detection of bladder cancer in high risk patients (NMP22 BladderChek).

AB - Bladder cancer is currently diagnosed using cystoscopy and cytology in patients with suspicious signs and symptoms. These tests are also used to monitor patients with a history of bladder cancer. The recurrence rate for bladder cancer is high, thus necessitating long-term follow-up. Urine cytology requires an experienced cytopathologist. It has high specificity, but low sensitivity for low-grade bladder tumors. Recently, multiple non-invasive urine-based bladder cancer tests have been developed. Many markers have already been approved by the Food and Drug Administration (FDA) for bladder cancer surveillance, but only one marker is approved for detection of bladder cancer in high risk patients (NMP22 BladderChek).

UR - http://www.scopus.com/inward/record.url?scp=58149473292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149473292&partnerID=8YFLogxK

U2 - 10.1309/DTJXKUDMQ49P80LR

DO - 10.1309/DTJXKUDMQ49P80LR

M3 - Article

AN - SCOPUS:58149473292

VL - 38

SP - 48

EP - 52

JO - Laboratory Medicine

JF - Laboratory Medicine

SN - 0007-5027

IS - 1

ER -